S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
Bear market expert makes new prediction (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
Here's something only a handful of people know (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
Bear market expert makes new prediction (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
Here's something only a handful of people know (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
Bear market expert makes new prediction (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
Here's something only a handful of people know (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
Bear market expert makes new prediction (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
Here's something only a handful of people know (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
NASDAQ:IMMP

Immutep (IMMP) Stock Forecast, Price & News

$2.13
-0.17 (-7.39%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$2.06
$2.23
50-Day Range
$1.54
$2.62
52-Week Range
$1.47
$3.90
Volume
646,800 shs
Average Volume
1.00 million shs
Market Capitalization
$187.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Immutep MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
369.5% Upside
$10.00 Price Target
Short Interest
Healthy
0.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Immutep in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.38) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

929th out of 1,010 stocks

Pharmaceutical Preparations Industry

464th out of 494 stocks


IMMP stock logo

About Immutep (NASDAQ:IMMP) Stock

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

IMMP Stock News Headlines

Comparing Immutep (NASDAQ:IMMP) & Vaccitech (NASDAQ:VACC)
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Immutep to Participate in Two Upcoming Investor Conferences
See More Headlines
Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

IMMP Company Calendar

Today
5/29/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMP
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+369.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$170,369.00
Book Value
$0.79 per share

Miscellaneous

Free Float
85,231,000
Market Cap
$187.29 million
Optionable
Not Optionable
Beta
2.39

Key Executives

  • Marc Voigt
    Chief Executive Officer, CFO & Executive Director
  • Deanne Miller
    COO, Secretary & General Counsel
  • David Fang
    Finance Director & Assistant Secretary
  • Florian D. Vogl
    Chief Medical Officer
  • Christian Mueller
    Vice President-Strategic Development













IMMP Stock - Frequently Asked Questions

What is Immutep's stock price forecast for 2023?

0 Wall Street analysts have issued twelve-month target prices for Immutep's stock. Their IMMP share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 369.5% from the stock's current price.
View analysts price targets for IMMP
or view top-rated stocks among Wall Street analysts.

How have IMMP shares performed in 2023?

Immutep's stock was trading at $1.75 at the beginning of 2023. Since then, IMMP shares have increased by 21.7% and is now trading at $2.13.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.09%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of Immutep?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $2.13.

How much money does Immutep make?

Immutep (NASDAQ:IMMP) has a market capitalization of $187.29 million and generates $170,369.00 in revenue each year.

How many employees does Immutep have?

The company employs 2,021 workers across the globe.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The official website for the company is www.immutep.com. The biotechnology company can be reached via phone at (128) 315-7003, via email at jay.campbell@immutep.com, or via fax at 61-2-8569-1880.

This page (NASDAQ:IMMP) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -